- decreased susceptibility to autoimmune diabetes / MGI
- periinsulitis / MGI
- decreased physiological sensitivity to xenobiotic / MGI
- decreased hematocrit / MGI
- abnormal liver physiology / MGI
- abnormal T cell differentiation / MGI
- abnormal cytokine secretion / MGI
- increased autoantibody level / MGI
- decreased susceptibility to parasitic infection / MGI
FVB/N(Cg)-H2b Tg(KRT14-HPV16)wt1Dh/Orl
Status | Available to order |
EMMA ID | EM:15289 |
International strain name | FVB/N(Cg)-H2b Tg(KRT14-HPV16)wt1Dh/Orl |
Alternative name | Tg(KRT14-HPV16)wt1Dh |
Strain type | Transgenic Strains |
Allele/Transgene symbol | Tg(KRT14-HPV16)wt1Dh, H2b |
Gene/Transgene symbol | Tg(KRT14-HPV16)wt1Dh, H2 |
Information from provider
Provider | Douglas Hanahan |
Provider affiliation | SV, EPFL/ISREC/Ludwig Lausanne |
Genetic information | The transgene is composed of 2 kb of the human K14 promoter/enhancer, regulating expression of the entire early region of HPV16. |
Phenotypic information | Homozygous:NAHeterozygous:During development the mice develop skin hyperplasia (ear) at 1 month of age, considered as DG1 in Switzerland for the animal experimentation criteria. Later the severity evolves, and the mice present skin dysplasia (3 months of age, DG1) followed by skin pruritus and ulcers (6 months of age, DG2, max degree at EPFL Lausanne). Finally, the mice develop some spontaneous skin cancer in 21% of mice between 8-12 months (DG3, not reached at EPFL Lausanne; Coussens et al., Am J Pathol. 1996,149(6):1899-917 - PMID:8952526) |
Breeding history | The K14HPV16/H2b line was generated by crossing K14HPV16-FVB/N (H2q) mice with C57BL/6 (H2b) mice to introduce the entire H2b locus, followed by backcrossing to FVB/N to render the mice congenic for H2b but otherwise genetically FVB/N. F1 mice were backcrossed for 11 generations to FVB/N, selecting for the H2b locus in every generation by flow cytometry analyses of H2Kb and H2Db. Afterwards, mice were intercrossed to generate homozygous H2b mice, expressing H2Kb and H2Db, but not H2Kq and H2D/Lq. The strain should be regarded as a double mutant strain as it carries the Tg(KRT14-HPV16)wt1Dh transgene and the H2b mutation inserted by previous backcrossing with C57BL/6 to FVB. The strain FVB.Cg-Tg(KRT14-HPV16)wt1Dh/Nci available through the NCI mouse repository (https://www.findmice.org/summary?gaccid=MGI:3047406) corresponds to our K14HPV16 old model with a full FVB/N background. As explained above and in Galliverti et al. (Cancer Immunol Res. 2018, 2020), our mice have been crossed with C57BL/6 mice to introduce the H2b locus. |
References |
|
Homozygous fertile | not known |
Homozygous viable | not known |
Homozygous matings required | yes |
Immunocompromised | no |
Information from EMMA
Archiving centre | Institut de Transgenose, INTRAGENE, Orléans, France |
Animals used for archiving | heterozygous FVB/N, wild-type FVB/N |
Stage of embryos | 2-cell |
Disease and phenotype information
MGI phenotypes (allele matching)
MGI phenotypes (gene matching)
- decreased hematocrit / MGI
- abnormal liver physiology / MGI
- abnormal T cell differentiation / MGI
- increased susceptibility to bacterial infection / MGI
- abnormal immunoglobulin level / MGI
- increased IgM level / MGI
- abnormal cytokine secretion / MGI
- thyroid inflammation / MGI
- increased autoantibody level / MGI
- insulitis / MGI
- increased susceptibility to autoimmune diabetes / MGI
- decreased susceptibility to autoimmune diabetes / MGI
- decreased susceptibility to parasitic infection / MGI
- immune system phenotype / MGI
- periinsulitis / MGI
- abnormal T cell number / MGI
- decreased CD4-positive, alpha beta T cell number / MGI
- increased CD8-positive, alpha-beta T cell number / MGI
- decreased IgG1 level / MGI
- decreased IgG2a level / MGI
- increased physiological sensitivity to xenobiotic / MGI
- decreased physiological sensitivity to xenobiotic / MGI
- increased sensitivity to induced morbidity/mortality / MGI
Literature references
- Myeloid Cells Orchestrate Systemic Immunosuppression, Impairing the Efficacy of Immunotherapy against HPV+ Cancers.;Galliverti Gabriele, Wullschleger Stephan, Tichet Mélanie, Murugan Dhaarini, Zangger Nadine, Horton Wesley, Korman Alan J, Coussens Lisa M, Swartz Melody A, Hanahan Douglas, ;2020;Cancer immunology research;8;131-145; 31771984
- Nanoparticle Conjugation of Human Papillomavirus 16 E7-long Peptides Enhances Therapeutic Vaccine Efficacy against Solid Tumors in Mice.;Galliverti Gabriele, Tichet Mélanie, Domingos-Pereira Sonia, Hauert Sylvie, Nardelli-Haefliger Denise, Swartz Melody A, Hanahan Douglas, Wullschleger Stephan, ;2018;Cancer immunology research;6;1301-1313; 30131378
Information on how we integrate external resources can be found here
INFRAFRONTIER® and European Mouse Mutant Archive - EMMA® are registered trademarks at the European Union Intellectual Property Office (EUIPO).